Добірка наукової літератури з теми "IL-5"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "IL-5".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Статті в журналах з теми "IL-5"
Kotsimbos, ATC, and Q. Hamid. "IL-5 and IL-5 receptor in asthma." Memórias do Instituto Oswaldo Cruz 92, suppl 2 (December 1997): 75–91. http://dx.doi.org/10.1590/s0074-02761997000800012.
Повний текст джерелаTAKATSU, Kiyoshi. "Interleukin-5, IL-5." Journal of Japan Atherosclerosis Society 23, no. 10 (1996): 599–603. http://dx.doi.org/10.5551/jat1973.23.10_599.
Повний текст джерелаMalhi, Gin S. "DSM-5: Il buono, il cattivo, il brutto." Australian & New Zealand Journal of Psychiatry 47, no. 7 (June 28, 2013): 595–98. http://dx.doi.org/10.1177/0004867413496363.
Повний текст джерелаNAKANISHI, KENJI. "Interleukin cascade of IL-4,IL-5 and IL-2." Japanese Journal of Clinical Immunology 13, no. 5 (1990): 438–40. http://dx.doi.org/10.2177/jsci.13.438.
Повний текст джерелаStein, Miguel L., Joyce M. Villanueva, Bridget K. Buckmeier, Yoshiyuki Yamada, Alexandra H. Filipovich, Amal H. Assa'ad, and Marc E. Rothenberg. "Anti–IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL-5 and IL-5 receptor levels." Journal of Allergy and Clinical Immunology 121, no. 6 (June 2008): 1473–83. http://dx.doi.org/10.1016/j.jaci.2008.02.033.
Повний текст джерелаWarren, H. S., B. F. Kinnear, J. H. Phillips, and L. L. Lanier. "Production of IL-5 by human NK cells and regulation of IL-5 secretion by IL-4, IL-10, and IL-12." Journal of Immunology 154, no. 10 (May 15, 1995): 5144–52. http://dx.doi.org/10.4049/jimmunol.154.10.5144.
Повний текст джерелаEsnault, Stephane, Mats W. Johansson, and Sameer K. Mathur. "Eosinophils, beyond IL-5." Cells 10, no. 10 (October 1, 2021): 2615. http://dx.doi.org/10.3390/cells10102615.
Повний текст джерелаTakatsu, Kiyoshi, and Hiroshi Nakajima. "IL-5 and eosinophilia." Current Opinion in Immunology 20, no. 3 (June 2008): 288–94. http://dx.doi.org/10.1016/j.coi.2008.04.001.
Повний текст джерелаChung, K. F. "IL-5 in asthma." Thorax 57, no. 8 (August 1, 2002): 751. http://dx.doi.org/10.1136/thorax.57.8.751.
Повний текст джерелаMatthaei, Klaus I., Paul S. Foster, and Ian G. Young. "The role of interleukin-5 (IL-5 ) in vivo: studies with IL-5 deficient mice." Memórias do Instituto Oswaldo Cruz 92, suppl 2 (December 1997): 63–68. http://dx.doi.org/10.1590/s0074-02761997000800010.
Повний текст джерелаДисертації з теми "IL-5"
Lundberg, Elin. "Utomståenderegeln i 57:5 IL." Thesis, Jönköping University, JIBS, Commercial Law, 2010. http://urn.kb.se/resolve?urn=urn:nbn:se:hj:diva-12225.
Повний текст джерелаAbstract This bachelor thesis deals with the close company rules in chapter 56-57 within the Swedish income tax law (IL). The purpose of this thesis is to analyse the outsider rule in 57:5 IL. If a shareholder or a family member works or have worked actively within the company within the fiscal year or the last five fiscal years then the partner has qualified shares and is to be taxed according to the special closed company rules. If an outsider, directly or indirectly, is a significant shareholder within the company, and directly or indirectly, are entitled to dividends then an active partner only has qualified shares if there is special reasons. When making the assessment regard must be made to conditions under the fiscal year or the last five fiscal years. There is special reason not to apply the rule if there are agreements regarding how the profit should be split or cross-ownerships between companies. If a taxpayer can show that an outsider own 30 percent of the closed company and has a right to dividends and there is no special reason to why the rule should not be applied then the outsider rule is applicable. If the rule is applicable it means that all the shareholders within the company will be taxed for dividends and capital gain with a 25 percent tax rate.
Krisiukėnienė, Algirda. "Rūkymo sąlygoti imuninio atsako ypatumai sergant astma." Doctoral thesis, Lithuanian Academic Libraries Network (LABT), 2009. http://vddb.library.lt/obj/LT-eLABa-0001:E.02~2009~D_20090604_110354-67472.
Повний текст джерелаAsthma is a chronic disorder of the airways, which is characterized by the presence of chronic airway inflammation. Experimental and clinical studies have showed that chronic airway inflammation is the most important part of asthma pathogenesis, which determines the clinical picture and severity of this disease. The data about differences and similarities of allergic and non-allergic asthma are questionable. It was considered that smoking might cause significant changes of bronchial mucosa. It is unclear whether smoking impairs immune response in patients with allergic and non-allergic asthma similarly. The aim of this study was to evaluate tobacco smoke-induced features of immune response in patients with allergic and non-allergic asthma. Subjects, with allergic and non-allergic asthma were investigated. According to their smoking habits, patients were divided into the groups: smokers and non-smokers. Tobacco smoke-induced changes of sputum and BAL fluid cellular composition were evaluated and features of inflammatory mediators (eotaxins, IL-5 and IL-9) were investigated. This study showed pathomorphological and pathophysiological differences between allergic and non-allergic asthma. Smoking impairs lung function and changes the pattern of chronic airway inflammation by decreasing production of cytokines and increasing production of chemokines.
Stomski, Frank Charles. "The molecular basis of IL-3, Il-5 and GM-CSF receptor activation /." Title page, contents and abstract only, 1997. http://web4.library.adelaide.edu.au/theses/09PH/09phs8766.pdf.
Повний текст джерелаNilsson, Linda, and Jenny Palm. "Utomståenderegeln 57 kap 5§ IL - är den ändamålsenlig?" Thesis, Kristianstad University College, Department of Business Administration, 2006. http://urn.kb.se/resolve?urn=urn:nbn:se:hkr:diva-3767.
Повний текст джерелаUppsatsens syfte är att beskriva vad utomståenderegeln innebär, vilka rekvisit som måste uppfyllas för att den ska vara tillämpbar och om den är ändamålsenlig enligt lagstiftarens syfte. Metoden som används är den rättsdogmatiska rättsvetenskapen, vilken innebär att en redogörelse gör för gällande rätt med hjälp av de olika rättskällorna, lag, förarbeten, praxis och doktrin. För att ge en helhetsbild används exempel för att illustrera olika situationer.
Till kategorin fåmansföretag räknas aktiebolag och ekonomisk förening, där fyra eller färre fysiska personer äger, direkt eller indirekt, så många aktier eller andelar att de tillsammans har mer än hälften av rösterna för samtliga aktier eller andelar i företaget. Det finns undantag som bidrar till att fåmansföretag inte omfattas av fåmansreglerna trots att de räknas till kategorin fåmansföretag. Ett av dessa undantag är utomståenderegeln.
Utomståenderegeln är en undantagsregel från 3:12-reglerna. Syftet med denna undantagsregel är att fåmansföretag med minst 30 % utomstående ägande befrias från de hårda beskattningsreglerna för fåmansföretag. Det finns vissa rekvisit som måste uppfyllas för att utomståenderegeln ska bli tillämpbar.
De slutsatser vi har kommit fram till är att sambor och stiftelser inte bör räknas som utomstående vilket de gör idag. Utomståenderegeln bör vidare vara obligatorisk för att inte undergräva skattemoralen. För att ytterligare förtydliga rekvisiten bör betydande del och gränsen för verksam i betydande omfattning preciseras i lagtext och förarbeten i den mån det är möjligt.
Det finns särskilda skäl som gör att utomståenderegeln inte kan tillämpas, vi anser att de särskilda skälen bör bortses från om det tydligt framgår att syftet inte varit att undgå 3:12-reglerna. Utomståenderegeln uppfyller till stor del sitt syfte. Vissa situationer kan dock ifrågasättas, t.ex. vid sambos och stiftelser som utomstående ägare.
Enligt dagens lagtext finns stort utrymme för tolkningar. Beträffande användning av förarbeten vid lagtolkningen, är det mot bakgrund av legalitetsprincipen viktigt att tolkningsresultatet underlättar förutsebarheten för den skatteskyldige.
Porte, Liliane Medianeira Favero. "Síntese de 5-hidróxi-3-(1,1-dimetoxietan-2-il)-5-trifluormetil-2-pirazolinas e 3-(1,1-difluoretan-2-il)-1H-pirazóis análogos." Universidade Federal de Santa Maria, 2008. http://repositorio.ufsm.br/handle/1/10417.
Повний текст джерелаThis work describes, at first, the synthesis of 4,6,6-trimethoxy-1,1,1-trifluorohex-3-en-2-one by the acylation reaction of 1,1,3,3-tetramethoxybutane, in 65% yields. Afterwards, the synthesis of a new series of 4,5-dihydro-1H-pyrazoles, which contain a ketal-protected aldehyde function as substituent, is described. These compounds are obtained by the reaction of 4,6,6-trimethoxy-1,1,1-trifluorohex-3-en-2-one with hydrazines (NH2NHR, R= 2-furoyl, C6F5, COOMe, COMe, Nicotinoyl), in 90-97% yields. In a subsequent step, dehydration reactions of 4,5-dihydro-1H-pyrazoles are reported, leading to 1H-pyrazoles. In addition, this work proposes a fluorination methodology of the ketal substituent of the 4,5-diidro-1H-pyrazoles and 1H-pyrazoles using diethylaminosulfur trifluoride (DAST). Finally, this work reports the desprotection of the ketal substituent to obtain the respective carbonyl compound and the subsequent fluorination reaction leading to the difluorinated analogues, in 55-60% yields. The compounds were characterized by 1H and 13C NMR experiments and by Mass Spectrometry, and their purity was confirmed by elemental analysis.
A presente dissertação descreve, inicialmente, a síntese de 4,6,6-trimetoxi-1,1,1-trifluorhex-3-en-2-ona através da reação de acilação do acetal 1,1,3,3-tetrametoxibutano, com rendimento de 65%. Subsequentemente é descrita a síntese de uma nova série de 4,5-diidro-1H-pirazóis, que possuem como substituinte uma função aldeído protegida sob a forma de acetal, obtidos a partir da reação de 4,6,6-trimetoxi-1,1,1-trifluorhex-3-en-2-ona com hidrazinas (NH2NHR, R= 2-furanoil, C6F5, COOMe, COMe, Nicotinoil), com rendimentos de 90-97%. Numa etapa posterior, são descritas as reações de desidratação dos 4,5-diidro-1Hpirazóis, as quais levaram ao isolamento dos respectivos 1H-pirazóis. Além disso, são propostas neste trabalho metodologias para a fluoração do substituinte acetal dos 4,5-diidro-1H-pirazóis e 1H-pirazóis, utilizando Dietilamino Trifluoreto de Enxofre (DAST). Finalmente, é descrito neste trabalho a etapa de desproteção do substituinte acetal para obtenção do composto carbonílico correspondente e posterior reação de fluoração levando ao isolamento dos análogos difluorados com rendimentos de 55-60%. Os compostos foram caracterizados por experimentos de RMN de 1H, RMN de 13C {1H} e por Espectrometria de Massas, e sua pureza comprovada por Análise Elementar.
Paim, Gisele Rocha. "Síntese de 2-(1h-pirazol-1-il)-5-(1h-pirazol-1-il-1-carbonil) piridinas." Universidade Federal de Santa Maria, 2008. http://repositorio.ufsm.br/handle/1/10419.
Повний текст джерелаThis work describes the synthesis of a new series of 2-[3-alkyl(aryl/heteroaryl)-5-trihalomethyl-5-hydroxy-4,5-dihydro-1H-pyrazol-1-il]-5-[3-alkyl(aryl/heteroaryl)-5-trihalomethyl-5-hydroxy-4,5-dihydro-1H-pyrazol-1-il-1-carbonyl]pyridines by the cyclocondensation reaction of 1,1,1-trihalo-4-alkoxy-4-alkyl(aryl/heteroaryl)-3-alken-2- ones [CX3C(O)CH=CR1OR, where R = Me, Et; R1 = H, Me, Ph, 4-MeOPh, 4-NO2Ph, 4,4 -Biphenyl, 1-Naftyl, 2-Furyl, 2-Thienyl and X = F, Cl] with 6-hydraninonicotinic hydrazide hydrate. Yields of 67 to 97% was obtained when the reactions were performed in ethanol as a solvent to 78 oC for 4 hours. In a subsequent step are described the reactions of dehydration intramolecular of 2- (1H-pyrazol-1-yl)-5-(1H pyrazol-1-yl-1-carbonyl)pyridines. These reactions were carried out in pyridine/benzene in the presence of thionyl chloride and led to the isolation of a series of 2- [3-alkyl (aryl/heteroaryl)-5-trihalomethyl-1H- pyrazol-1-yl]-5-3-alkyl (aryl/heteroaryl)-5-trihalomethyl-1H-pyrazol-1-yl-1-carbonyl]pyridine, with yields of 64 to 86%. All compounds were characterized by analytical experiments 1Hs and 13Cs, 2DCOLOQ NMR, mass spectrometry (GC-MSD) and its purities they were determined by CHN elemental analysis.
Esta dissertação apresenta a síntese de uma nova série de 2-[3-alquil (aril/heteroaril)-5-trialometil-5-hidroxi-4,5-diidro-1H-pirazol-1-il]-5-[3- alquil(aril/heteroaril)-5-trialometil-5-hidroxi-4,5-diidro-1H-pirazol-1-il-1- carbonil]piridinas, obtida a partir de reações de ciclocondensação de 1,1,1-trialo-4- alquil(aril/heteroaril)-4-alcoxi-3-alquen-2-onas [CX3C(O)CH=CR1OR, onde R = Me, Et; R1 = H, Me, Ph, 4-MeOPh, 4-NO2Ph, 4,4 -Bifenil, 1-Naftil, Fur-2-il e Tien-2-il e X = F, Cl] com hidrazida 6-hidrazino nicotínica. Rendimentos de 67 a 97% foram obtidos quando as reações foram executadas em etanol como solvente a 78 oC por 4 horas. Numa etapa posterior, são descritas as reações de desidratação intramolecular de 2- (1H-pirazol-1-il)-5-(1H-pirazol-1-il-1-carbonil) piridinas. Estas reações foram realizadas em meio piridina/benzeno, na presença de cloreto de tionila e levaram ao isolamento de uma série de 2-[3-alquil(aril/heteroaril)-5-trifluormetil-1H-pirazol-1-il]-5-[3-alquil (aril/ heteroaril)-5-trifluormetil-1H-pirazol-1-il-1-carbonil]piridina, com rendimentos de 64 a 86%. Os compostos foram caracterizados por experimentos de RMN de 1H, RMN de 13C {1H} e RMN 2D COLOQ, espectroscopia de massas (GC-MSD) e as suas purezas foram determinadas por análise elementar CHN.
Nogara, Pablo Andrei. "Síntese de (5-trifluormetil-1H-pirazol-1-IL)(quinolin-4-IL)metanonas de interesse farmacológico." Universidade Federal de Santa Maria, 2016. http://repositorio.ufsm.br/handle/1/10627.
Повний текст джерелаA convergent synthesis of a series of 16 new polysubstituted (5-hydroxy-5-(trifluoromethyl)-4,5-dihydro-1H-pyrazol-1-yl)(quinolin-4-yl)methanones, starting from isatin and alky(aryl/heteroaryl) ketones, is described. The diheteroaryl methanones were achieved at yields of up to 95% by a (3 + 2) cyclocondensation reaction involving 4-alkyl(aryl/heteroaryl)-4-methoxy-1,1,1-trifluorobut-3-en-2-ones (by two-step reaction) and 2-alkyl(aryl/heteroaryl)-4-carbohydrazides (by three-step reaction). Subsequently, representative dehydrated heterocyclic derivatives were obtained from the respective 5-hydroxy-2-pyrazoline moieties by classical dehydration reactions, which resulted in the corresponding (5-(trifluoromethyl)-1H-pyrazol-1-yl)(quinolin-4-yl)methanones (three examples) at yields of 69 82%. The compounds were characterized by one- and two-dimensional 1H/13C NMR, X-ray diffraction, GC-MS and elemental analysis. The subsequent cytotoxicity evaluation showed that compounds with aromatic groups at the 2-position of the quinoline and a methyl moiety at the 3-position of the pyrazole have significant cytotoxicity in human leukocytes at high concentrations (200 μM).
Uma síntese convergente de uma série de 16 novos poli-substituídos (5-hidroxi-5-(trifluorometil)-4,5-di-hidro-1H-pirazol-1-il)(quinolin-4-il)metanonas, a partir da isatina e alquil(aril/heteroaril)cetonas, é descrito. As diheteroarilmetanonas foram obtidas com rendimentos de até 95% por uma reação de ciclocondensação (3 + 2) envolvendo 4-alquil(aril/heteroaril)-4-metóxi-1,1,1-trifluorbut-3-en-2-onas (reação em dois passos) e 2-alquil(aril/heteroaril)-4-carbohidrazidas (reação em três passos). Subsequentemente, os representantes desidratados dos heterociclos foram obtidos a partir das respectivas porções de 5-hidróxi-2-pirazolina por reações de desidratação clássicas, o que resultou nas correspondentes (5-(trifluormetil)-1H-pirazol-1-il)(quinolin-4-il )metanonas (três exemplos) com rendimentos de 69-82%. Os compostos foram caracterizados por RMN de 1H e 13C uni e bidimensional, difração de raios-X, CG-EM e análise elementar. As posteriores avaliações da citotoxicidade mostraram que os compostos com grupos aromáticos na posição 2 da quinolina e o grupo metila na posição 3 do pirazol, possuem significativa citotoxicidade em leucócitos humanos em concentrações elevadas (200 μM).
Monduzzi, Pietro. "Applicare il design thinking a progetti ad elevato TRL (5-7): riflessioni metodologiche e il caso M.A.T.R.I.C.S." Master's thesis, Alma Mater Studiorum - Università di Bologna, 2022.
Знайти повний текст джерелаSun, Qiyu. "Human GM-CSF, IL-3 and IL-5 receptor expression and their functional domains studied with monoclonal antibodies /." Title page, contents and abstract only, 1997. http://web4.library.adelaide.edu.au/theses/09PH/09phs9569.pdf.
Повний текст джерелаBorgwardt, Derek Steven. "Histatin 5 attenuates IL-8 dendritic cell response to gingivalis Hemagglutinin B." Thesis, University of Iowa, 2011. https://ir.uiowa.edu/etd/926.
Повний текст джерелаКниги з теми "IL-5"
Kim, Myŏng-sŏn. Che-5 Konghwaguk 444-il. Sŏul: Pʻyŏngbŏm Sŏdang, 1988.
Знайти повний текст джерела5-wŏl 18-il, Kwangju. Sŏul-si: Yŏksa Kong'gan, 2010.
Знайти повний текст джерелаYi, Tŏk-pong. Che-5 Konghwaguk 444-il. Sŏul: Koryŏ Kihoek, 1988.
Знайти повний текст джерелаKim, Il-sŏng. Choguk Kwangbokhoe kyuyak, 1936-yŏn 5-wŏl 5-il. [Pʻyŏngyang]: Chosŏn Nodongdang Chʻulpʻansa, 1988.
Знайти повний текст джерелаMonina, Michele. Il perchè di una vittoria: Il Movimento 5 stelle. Roma: Moralia, 2013.
Знайти повний текст джерелаIl fine della chiocciola: 5 storie. Roma: Albatros Il filo, 2010.
Знайти повний текст джерелаChangjinho tongtchok: 4-il nat 5-il pam ŭi pirok. Sŏul-si: Tat'ŭaen, 2013.
Знайти повний текст джерелаMunhwa ro toesaranan Namdo 5-il chang. Sŏul: Minsogwŏn, 2010.
Знайти повний текст джерелаKang, In-sun. Kang In-sun mok kongyejŏn, 2001. 5. 16(su) - 5. 27 (il). Kyŏnggi-do Sŏngnam-si: Gaellŏri Samsŏng Pʻŭllaja, 2001.
Знайти повний текст джерела2002 Han-Il Wŏldŭkʻŏp Chosŏn Ilbo kʻŏllŏ chʻukswaepʻan: 5-wŏl 31-il-7-wŏl 10-il. Sŏul Tʻŭkpyŏlsi: Chosŏn Ilbosa, 2002.
Знайти повний текст джерелаЧастини книг з теми "IL-5"
Pelaia, Girolamo, Alessandro Vatrella, and Rosario Maselli. "IL-5-Targeted Antibodies." In Asthma: Targeted Biological Therapies, 51–66. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-46007-9_5.
Повний текст джерелаSchroeder, John T. "Diagnostic Components: T Helper Cell Cytokines (IL-4, IL-5, IL-9, IL-10, IL-13, IL-17)." In Encyclopedia of Medical Immunology, 221–26. New York, NY: Springer New York, 2014. http://dx.doi.org/10.1007/978-1-4614-9194-1_298.
Повний текст джерелаKhan, Manzoor M. "Regulation of IL-4 and IL-5 Secretion by Histamine and PGE2." In Advances in Experimental Medicine and Biology, 35–42. Boston, MA: Springer US, 1995. http://dx.doi.org/10.1007/978-1-4615-1891-4_5.
Повний текст джерелаMui, Alice, Akihiko Muto, Kazuhiro Sakamaki, Noriko Sato, Taisei Kinoshita, Sumiko Watanabe, Takashi Yokota, Kenichi Arai, and Atsushi Miyajima. "Function of the Common β Subunit of the GM-CSF/IL-3/IL-5 Receptors." In Advances in Experimental Medicine and Biology, 217–23. Boston, MA: Springer US, 1994. http://dx.doi.org/10.1007/978-1-4899-0987-9_22.
Повний текст джерелаChang, Yun-Ke, Schubert Foo, and Shaheen Majid. "Assessing IL Skills of Primary-5 Students in Singapore." In Communications in Computer and Information Science, 531–39. Cham: Springer International Publishing, 2014. http://dx.doi.org/10.1007/978-3-319-14136-7_56.
Повний текст джерелаMori, Akio, Matsunobu Suko, Osamu Kaminuma, Yoko Nishizaki, Toshifumi Nagahori, Tadashi Mikami, Takeo Ohmura, Akihiko Hosino, Yumiko Asakura, and Hirokazu Okudaira. "Enhanced Production and Gene Expression of IL-5 in Bronchial Asthma." In Advances in Experimental Medicine and Biology, 439–50. Boston, MA: Springer US, 1996. http://dx.doi.org/10.1007/978-1-4615-5855-2_64.
Повний текст джерелаCompare, Angelo, Enzo Grossi, Elena Germani, Luca Domeneghetti, A. Zielllo, and Claudio Zullo. "Verso il DSM-5: Scenari nosologici delle patologie legate allo stress." In Stress e disturbi da somatizzazione, 357–83. Milano: Springer Milan, 2012. http://dx.doi.org/10.1007/978-88-470-2080-1_23.
Повний текст джерелаMarshall, Richard, and Isidore Faiferman. "IL-5-directed approaches in the treatment of eosinophil-driven disease." In New Drugs and Targets for Asthma and COPD, 103–7. Basel: KARGER, 2010. http://dx.doi.org/10.1159/000320806.
Повний текст джерелаPaquet, Luc, Paolo Renzi, Nicolay Ferrari, and Mark Parry-Billings. "A multitargeted antisense therapy directed at CCR3 and the common β-chain of IL-3/IL-5/GM-CSF." In New Drugs and Targets for Asthma and COPD, 297–302. Basel: KARGER, 2010. http://dx.doi.org/10.1159/000320834.
Повний текст джерелаYokota, T., H. Hagiwara, Y. Takebe, T. Otsuka, A. Miyajima, P. Meyerson, P. Hoy, et al. "Isolation and Characterization of Mouse and Human cDNA Clones Encoding IL-4 and IgA-Enhancing Factor/Eosinophil CSF (IL-5)." In Molecular Basis of Lymphokine Action, 313–24. Totowa, NJ: Humana Press, 1987. http://dx.doi.org/10.1007/978-1-4612-4598-8_28.
Повний текст джерелаТези доповідей конференцій з теми "IL-5"
Dimitrova, Denitsa, Vania Youroukova, Tsvetelina Velikova, and Kalina Tumangelova-Yuzeir. "Serum levels of IL-5, IL-6 and IL-8 in moderate and severe asthma clusters." In ERS International Congress 2018 abstracts. European Respiratory Society, 2018. http://dx.doi.org/10.1183/13993003.congress-2018.pa5060.
Повний текст джерелаDomagala-Kulawik, J., A. Safianowska, H. Grubek-Jaworska, and R. Chazan. "IL-5 Concentration and BALF Eosinophilia – Diagnostic Value." In American Thoracic Society 2009 International Conference, May 15-20, 2009 • San Diego, California. American Thoracic Society, 2009. http://dx.doi.org/10.1164/ajrccm-conference.2009.179.1_meetingabstracts.a3696.
Повний текст джерелаLinch, Stefanie N., Ann Kelly, Erin Danielson, and Jeffrey A. Gold. "IL-5 Augments Macrophage Function In Polymicrobial Sepsis." In American Thoracic Society 2010 International Conference, May 14-19, 2010 • New Orleans. American Thoracic Society, 2010. http://dx.doi.org/10.1164/ajrccm-conference.2010.181.1_meetingabstracts.a1802.
Повний текст джерелаPatel, Katir K., Paul S. Salva, and Wilmore C. Webley. "Increased Secretion Of Interleukin-5 (IL-5) And IL-13 In The Lungs Of Pediatric Patients Infected With Chlamydia Organisms." In American Thoracic Society 2010 International Conference, May 14-19, 2010 • New Orleans. American Thoracic Society, 2010. http://dx.doi.org/10.1164/ajrccm-conference.2010.181.1_meetingabstracts.a3276.
Повний текст джерелаAllinne, Jeanne, George Scott, Dylan Birchard, Seblewongel Asrat, Kirsten Nagashima, Audrey Le Floc’H, Matthew A. Sleeman, Andrew J. Murphy, George D. Yancopoulos, and Jamie M. Orengo. "Broader Impact of IL-4Ra Blockade Than IL-5 Blockade on Type 2 Inflammation." In ERS International Congress 2019 abstracts. European Respiratory Society, 2019. http://dx.doi.org/10.1183/13993003.congress-2019.pa3877.
Повний текст джерелаMaruoka, Shuichiro, Ryoji Ito, Mamoru Ito, Satoshi Nunomura, Kenji Izuhara, Yasuhiro Gon, Kaori Soda, Shu Hashimoto, and Shoichiro Ota. "Development of IL-33-induced asthmatic airway inflammation in human IL-3/GM-CSF/IL-5-transgenic NOG mice." In ERS International Congress 2017 abstracts. European Respiratory Society, 2017. http://dx.doi.org/10.1183/1393003.congress-2017.pa573.
Повний текст джерелаNaselsky, Warren C., Kelly D. Chason, Xiaoyang Hua, and Stephen L. Tilley. "IL-4 Primes Human Mast Cells To Secrete IL-5, IL-13, And PGD2 In Response To LPS Stimulation." In American Thoracic Society 2012 International Conference, May 18-23, 2012 • San Francisco, California. American Thoracic Society, 2012. http://dx.doi.org/10.1164/ajrccm-conference.2012.185.1_meetingabstracts.a5732.
Повний текст джерелаSelvaraja, M., M. Abdullah, A. Md Shah, MB Arip, and S. Amin Nordin. "314 Role of cytokine il-5 and il-25 as biomarkers in systemic lupus erythematosus." In LUPUS 2017 & ACA 2017, (12th International Congress on SLE &, 7th Asian Congress on Autoimmunity). Lupus Foundation of America, 2017. http://dx.doi.org/10.1136/lupus-2017-000215.314.
Повний текст джерелаSaji, Junko, Hiromi Muraoka, Eriko Nishimoto, Shin Matsuzawa, Mariko Okamoto, Teppei Inoue, Hiroshi Handa, et al. "Effectiveness of anti-IgE and anti-IL-5 treatment in step 5 asthma patients." In ERS International Congress 2018 abstracts. European Respiratory Society, 2018. http://dx.doi.org/10.1183/13993003.congress-2018.pa1131.
Повний текст джерелаJackson, David J., Maria-Belen Trujillo-Torralbo, Jerico del Rosario, Aurica Telcian, Alexandra Nikonova, Julia Aniscenko, Leila Gogsadze, et al. "Rhinovirus Induces IL-4, IL-5 And IL-13 In The Airways In Asthma But Not In Non-Atopic Subjects." In American Thoracic Society 2012 International Conference, May 18-23, 2012 • San Francisco, California. American Thoracic Society, 2012. http://dx.doi.org/10.1164/ajrccm-conference.2012.185.1_meetingabstracts.a6874.
Повний текст джерелаЗвіти організацій з теми "IL-5"
Rink, George, and Carl A. Budelsky. Proceedings of the 7th central hardwood conference; 1989 March 5-8; Carbondale, IL. St. Paul, MN: U.S. Department of Agriculture, Forest Service, North Central Forest Experiment Station, 1989. http://dx.doi.org/10.2737/nc-gtr-132.
Повний текст джерелаCordts, Jerome R. Annual Conference on Human Retrovirus Testing (7th) held in Chicago, IL on March 3-5, 1992. Fort Belvoir, VA: Defense Technical Information Center, April 1993. http://dx.doi.org/10.21236/ada262160.
Повний текст джерелаCao, Xianling, Xuanyou Zhou, Naixin Xu, Songchang Chang, and Chenming Xu. Association of IL-4 and IL-10 Polymorphisms with Preterm Birth Susceptibility: A Systematic Review and Meta-Analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, April 2022. http://dx.doi.org/10.37766/inplasy2022.4.0044.
Повний текст джерелаLiu, Miao, Hongan Wang, Jing Lu, Zhiyue Zhu, Chaoqun Song, Ye Tian, Xinzhi Chen, et al. Vitamin D supplementation in the treatment of Myasthenia Gravis A protocol for a systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, September 2022. http://dx.doi.org/10.37766/inplasy2022.9.0129.
Повний текст джерелаElmann, Anat, Orly Lazarov, Joel Kashman, and Rivka Ofir. therapeutic potential of a desert plant and its active compounds for Alzheimer's Disease. United States Department of Agriculture, March 2015. http://dx.doi.org/10.32747/2015.7597913.bard.
Повний текст джерелаRipoll, Santiago, Tabitha Hrynick, Ashley Ouvrier, Megan Schmidt-Sane, Federico Marco Federici, and Elizabeth Storer. 10 façons dont les gouvernements locaux en milieu urbain multiculturel peuvent appuyer l’égalité vaccinale en cas de pandémie. SSHAP, January 2023. http://dx.doi.org/10.19088/sshap.2023.001.
Повний текст джерелаFunkenstein, Bruria, and Shaojun (Jim) Du. Interactions Between the GH-IGF axis and Myostatin in Regulating Muscle Growth in Sparus aurata. United States Department of Agriculture, March 2009. http://dx.doi.org/10.32747/2009.7696530.bard.
Повний текст джерелаFicht, Thomas, Gary Splitter, Menachem Banai, and Menachem Davidson. Characterization of B. Melinensis REV 1 Attenuated Mutants. United States Department of Agriculture, December 2000. http://dx.doi.org/10.32747/2000.7580667.bard.
Повний текст джерела